Key insights
- Adlai Nortye (ANL) is raising $150M via a private placement of ADSs at $13.25, an oversubscribed deal with new and existing institutional investors. While the financing supports their cancer therapy development, the stock's recent 833% YTD gain and overbought RSI suggest caution. The deal itself has a slightly negative influence as it introduces new shares, potentially diluting existing holders, although the institutional backing provides some offset.
SINGAPORE and NORTH BRUNSWICK, N.J. - Adlai Nortye Ltd. (NASDAQ:ANL) announced today it has entered into a securities purchase agreement for a private investment in public equity financing expected to generate gross proceeds of approximately $150 million before fees and expenses.
The clinical-stage biotechnology company focused on cancer therapies is selling 11,320,755 American Depositary Shares at $13.25 per ADS, matching the closing price on the Nasdaq Global Market on Tuesday. The transaction is oversubscribed and includes participation from both new and existing institutional investors, according to a press release statement.The financing comes amid remarkable stock momentum, with shares delivering an 833% return year-to-date and a 723% gain over the past six months. According to InvestingPro Tips, the stock has shown significant returns over the last week and trades in overbought territory based on RSI indicators. The company currently holds a market cap of $489 million, though InvestingPro analysis suggests the stock may be overvalued at current levels. Investors can access 15 additional ProTips and comprehensive financial metrics on the platform.
New investors in the private placement include Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management, Kalehua Capital, and DAFNA Capital Management. Existing investors participating include Cormorant Asset Management, Columbia Threadneedle Investments, Balyasny Asset Management, Casdin Capital, Squadron Capital Management, and Superstring Capital Management.
The private placement is expected to close on Friday, subject to customary closing conditions.
"We are delighted to have brought together this group of high-quality healthcare investors to support Adlai Nortye and our innovative, potentially best-in-class RAS-targeting therapies," said Carsten Lu, Chairman and Chief Executive Officer.
Leerink Partners, Cantor, Lucid Capital Markets, H.C. Wainwright & Co., and Jones are serving as joint placement agents for the transaction.
The company stated that the securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption. Adlai Nortye has agreed to file a registration statement with the Securities and Exchange Commission for the resale of the ADSs issued in the private placement.
The company is developing cancer therapies including RAS-targeting treatments and next-generation cancer immunotherapies.
In other recent news, Adlai Nortye Ltd. has secured approximately $140 million through a private investment in public equity financing. The company sold 64,615,386 Class A ordinary shares, equating to 21,538,462 American Depositary Shares, at $2.1667 per Class A ordinary share or $6.50 per ADS. Additionally, H.C. Wainwright upgraded Adlai Nortye’s stock rating from Neutral to Buy, setting a price target of $16.00. This upgrade reflects H.C. Wainwright’s positive outlook on Adlai Nortye’s clinical portfolio, particularly the asset AN9025, which is seen as a major contributor to the company’s value. Lucid Capital Markets also initiated coverage on Adlai Nortye with a Buy rating and a price target of $11.00. Their analysis highlights the potential significance of AN9025 as a value driver for the stock. These developments underscore a period of strategic financial and analytical activity for Adlai Nortye.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.